Herein, we detected PIM-1 expression in CTCs of EGFRm NSCLC patients before osimertinib and at PD, suggesting that concurrent use of PIM-1 inhibitors with osimertinib could be a possible therapeutic strategy. The gene discussed is PIM1; the disease is non-small cell lung carcinoma.